The global isovaleric acidemia treatment market is expected to reach a valuation of US$ 652.28 Million in 2023 and is projected to reach US$ 1,125.15 by 2033, trailing at a CAGR of 5.6%. Presently, genetic screening using mass spectrometry and DNA testing among all newborns is carried out in almost all of the developed nations of the world and also in developing economies of India, Brazil, and China. This helps uncover inherited metabolic disorders (IMD) at an early stage which is driving the market growth.
However, among many adult populations and in some children, rare genetic metabolic disorders are abruptly presented and often not accurately diagnosed. In such individuals, abnormal metabolic changes are considered to be a type of genetic mutation in routine diagnosis. The treatment of IMDs is broadly classified into dietary restrictions, dietary supplementation, drugs that inhibit or regulate metabolism, transplantation of the concerned organ, gene therapy, and dialysis in severe cases. In the case of familial chylomicronemia, gene therapy includes Alipogene tiparvovec recombinant gene therapy drug, manufactured by UniQure Inc.
This therapy utilizes viruses (adenovirus vector) designed in such a way that upon infection, the gene for producing the lipoprotein lipase is induced into the host cell, thereby producing the enzyme in-vivo. This therapy has shown positive results and is expected to be released into the market soon which presents opportunistic prospects for market expansion. For now, the global inherited metabolic disorders Market lies broadly in the dietary supplements market which is supporting market growth.
The use of genetic markers in T-cell receptor excision circles for severe combined immunodeficiency is one promising technique that augments market expansion. Moreover, the use of tandem mass spectrometry for the diagnosis of inborn errors of metabolism has the potential to expand the newborn screening panel which will propel the diagnostic market for isovaleric acidemia treatment.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | US$ 652.28 Million |
Anticipated Forecast Value (2033) | US$ 1,125.15 Million |
Projected Growth Rate (2023 to 2033) | CAGR 5.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The isovaleric acidemia treatment market was valued at US$ 520 Million in 2018 while exhibiting a CAGR of 4.64%. Adoption of new technology such as mRNA in metabolic testing procedures is expected to shift the pharmaceutical industry to new heights which are augmenting the demand for the Isovaleric Acidemia treatment market. Considering these factors, the market is estimated to be valued at US$ 1,125.15 Million, growing at a CAGR of 5.6% by end of the forecast period.
The advent of new technologies in IVA fuelling market growth
The advent of tandem mass spectrometry expanded newborn screening (NBS) and has become a mandatory public health strategy in most developed and developing countries, which will drive market growth. Moreover, this technology allows inexpensive simultaneous detection of more than 30 different metabolic disorders like Isovaleric Acidemia Treatment, in one single blood spot specimen at a cost of about US$ 10 per baby, with commendable analytical accuracy and precision, which will bolster the demand for Isovaleric Acidemia Treatment drug and therapeutics during the forecast period. studies have confirmed that the savings achieved through the use of expanded NBS programs are significantly greater than the costs of implementation.
Autonomy for local screening agencies to develop their screening programs in order to keep pace with international advancements is expected to support market expansion. Integration of existing clinical IEM services with the expanded NBS program to enable close communication between the laboratory, clinicians, and allied health parties.
The adjuvant therapy with sapropterin is also helpful for PKU treatment. In recent years, private medical insurers in the US and a few other countries are also offering reimbursement programs for the consumption of certain medical foods. Thus, the rising adoption of medical food and nutrient supplements is expected to foster market growth during the forecast period.
High cost of diagnostic treatment restraining market expansion
Inadequate reimbursement scenario, high cost of treatment and delayed adoption of new emerging diagnostic and therapeutic technologies will restrain the market growth during the forecast period.
North America was the largest market for Isovaleric Acidemia Treatment therapeutics with a market share of 41.8% in 2022. The market revenue in this region is projected to be valued at around US$ 520 Million by 2033. It is likely to show prominent growth while retaining its dominance during the forecast period. This is due to the increase in demand for sapropterin and kuvan for amino acid metabolism disorders treatments in the region. Moreover, the region boasts of a wide availability of treatments and a well-established healthcare infrastructure.
The extensive presence of several end-users focusing on treatment and studies of chronic disease makes use of metabolomics, and this is the primary driver of market growth in the region. The active participation of the government in the form of investment and world-class resources for research activities is driving the growth of the metabolomics market in the region of Canada.
The market in Asia Pacific is estimated to be valued at US$ 350 Million, trailing at a CAGR of 4.9% during the forecast period. Growing investments in diagnostic healthcare, increasing adoption of new technologies, rising prevalence of inherited metabolic disorders in other regions, and increasing awareness regarding health are fuelling the demand for isovaleric acidemia disorder therapeutics in the region. China is expected to dominate the Inborn errors of metabolism market with more than 41% market share in this region owing to the rapid adoption of mRNA technology in diagnostics and surging advancements in the medical sector.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The supplements carnitine and glycine can reduce the toxicity of isovaleric acid and aid in its removal from the body. L-Carnitine supplements are expected to dominate the treatment segment with a share of 79% and are projected to retain the highest weight during the forecast period.
Administration of equimolar amounts of glycine or L-carnitine separately with leucine demonstrated that isovaleryl-coenzyme A is removed by supplemental L-carnitine in the form of isovalerylcarnitine as effectively as it is by glycine, in the form of isovalerylglycine. Treatment with L-carnitine alone has proven effective in preventing further hospitalizations in a patient with this disorder, which will drive the segment growth by end of the forecast period.
Key players in the Isovaleric Acidemia Treatment Market are Amgen, Replimune Group Inc., Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, VCNBiosciences, DNAtrix.
Some Recent Developments in this industry are:
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 652.28 Million |
Market Value in 2033 | US$ 1,125.15 Million |
Growth Rate | CAGR of 5.6% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in US Million and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
FMI projects the global Isovaleric Acidemia Treatment Market to expand at a 5.6% value CAGR by 2033.
The global Isovaleric Acidemia Treatment Market is expected to garner a market value of US$ 1,125.15 Million by 2033.
FMI has projected North America to be one of the most profitable regions for the Isovaleric Acidemia Treatment Market.
APAC region is expected to grow fastest during the forecast period.
1. Executive Summary | Isovaleric Acidemia Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Investment Feasibility Matrix 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Glycine supplements 5.3.2. L-carnitine supplements 5.3.3. Others 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 6.1. Introduction 6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 6.3.1. North America 6.3.2. Latin America 6.3.3. Europe 6.3.4. Asia Pacific 6.3.5. Middle East and Africa 6.4. Market Attractiveness Analysis By Region 7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 7.2.1. By Country 7.2.1.1. The US 7.2.1.2. Canada 7.2.2. By Treatment 7.3. Market Attractiveness Analysis 7.3.1. By Country 7.3.2. By Treatment 7.4. Key Takeaways 8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. Brazil 8.2.1.2. Mexico 8.2.1.3. Rest of Latin America 8.2.2. By Treatment 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment 8.4. Key Takeaways 9. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Germany 9.2.1.2. The UK 9.2.1.3. France 9.2.1.4. Spain 9.2.1.5. Italy 9.2.1.6. Russia 9.2.1.7. Rest of Europe 9.2.2. By Treatment 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.4. Key Takeaways 10. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. China 10.2.1.2. Japan 10.2.1.3. India 10.2.1.4. South Korea 10.2.1.5. Australia 10.2.1.6. Rest of APAC 10.2.2. By Treatment 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.4. Key Takeaways 11. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. South Africa 11.2.1.2. Saudi Arabia 11.2.1.3. UAE 11.2.1.4. Israel 11.2.1.5. Rest of MEA 11.2.2. By Treatment 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.4. Key Takeaways 12. Key Countries Market Analysis 12.1. The US 12.1.1. Pricing Analysis 12.1.2. Market Share Analysis, 2022 12.1.2.1. By Treatment 12.2. Canada 12.2.1. Pricing Analysis 12.2.2. Market Share Analysis, 2022 12.2.2.1. By Treatment 12.3. Brazil 12.3.1. Pricing Analysis 12.3.2. Market Share Analysis, 2022 12.3.2.1. By Treatment 12.4. Mexico 12.4.1. Pricing Analysis 12.4.2. Market Share Analysis, 2022 12.4.2.1. By Treatment 12.5. Germany 12.5.1. Pricing Analysis 12.5.2. Market Share Analysis, 2022 12.5.2.1. By Treatment 12.6. The UK 12.6.1. Pricing Analysis 12.6.2. Market Share Analysis, 2022 12.6.2.1. By Treatment 12.7. France 12.7.1. Pricing Analysis 12.7.2. Market Share Analysis, 2022 12.7.2.1. By Treatment 12.8. Spain 12.8.1. Pricing Analysis 12.8.2. Market Share Analysis, 2022 12.8.2.1. By Treatment 12.9. Italy 12.9.1. Pricing Analysis 12.9.2. Market Share Analysis, 2022 12.9.2.1. By Treatment 12.10. Russia 12.10.1. Pricing Analysis 12.10.2. Market Share Analysis, 2022 12.10.2.1. By Treatment 12.11. China 12.11.1. Pricing Analysis 12.11.2. Market Share Analysis, 2022 12.11.2.1. By Treatment 12.12. Japan 12.12.1. Pricing Analysis 12.12.2. Market Share Analysis, 2022 12.12.2.1. By Treatment 12.13. India 12.13.1. Pricing Analysis 12.13.2. Market Share Analysis, 2022 12.13.2.1. By Treatment 12.14. South Korea 12.14.1. Pricing Analysis 12.14.2. Market Share Analysis, 2022 12.14.2.1. By Treatment 12.15. Australia 12.15.1. Pricing Analysis 12.15.2. Market Share Analysis, 2022 12.15.2.1. By Treatment 12.16. South Africa 12.16.1. Pricing Analysis 12.16.2. Market Share Analysis, 2022 12.16.2.1. By Treatment 12.17. Saudi Arabia 12.17.1. Pricing Analysis 12.17.2. Market Share Analysis, 2022 12.17.2.1. By Treatment 12.18. UAE 12.18.1. Pricing Analysis 12.18.2. Market Share Analysis, 2022 12.18.2.1. By Treatment 12.19. Israel 12.19.1. Pricing Analysis 12.19.2. Market Share Analysis, 2022 12.19.2.1. By Treatment 13. Market Structure Analysis 13.1. Competition Dashboard 13.2. Competition Benchmarking 13.3. Market Share Analysis of Top Players 13.3.1. By Regional 13.3.2. By Treatment 14. Competition Analysis 14.1. Competition Deep Dive 14.1.1. Amgen 14.1.1.1. Overview 14.1.1.2. Product Portfolio 14.1.1.3. Profitability by Market Segments 14.1.1.4. Sales Footprint 14.1.1.5. Strategy Overview 14.1.1.5.1. Marketing Strategy 14.1.2. Replimune Group Inc. 14.1.2.1. Overview 14.1.2.2. Product Portfolio 14.1.2.3. Profitability by Market Segments 14.1.2.4. Sales Footprint 14.1.2.5. Strategy Overview 14.1.2.5.1. Marketing Strategy 14.1.3. Transgene SA 14.1.3.1. Overview 14.1.3.2. Product Portfolio 14.1.3.3. Profitability by Market Segments 14.1.3.4. Sales Footprint 14.1.3.5. Strategy Overview 14.1.3.5.1. Marketing Strategy 14.1.4. Oncolys BioPharma 14.1.4.1. Overview 14.1.4.2. Product Portfolio 14.1.4.3. Profitability by Market Segments 14.1.4.4. Sales Footprint 14.1.4.5. Strategy Overview 14.1.4.5.1. Marketing Strategy 14.1.5. Targovax 14.1.5.1. Overview 14.1.5.2. Product Portfolio 14.1.5.3. Profitability by Market Segments 14.1.5.4. Sales Footprint 14.1.5.5. Strategy Overview 14.1.5.5.1. Marketing Strategy 14.1.6. Lokon Pharma 14.1.6.1. Overview 14.1.6.2. Product Portfolio 14.1.6.3. Profitability by Market Segments 14.1.6.4. Sales Footprint 14.1.6.5. Strategy Overview 14.1.6.5.1. Marketing Strategy 14.1.7. Vyriad 14.1.7.1. Overview 14.1.7.2. Product Portfolio 14.1.7.3. Profitability by Market Segments 14.1.7.4. Sales Footprint 14.1.7.5. Strategy Overview 14.1.7.5.1. Marketing Strategy 14.1.8. TILT Biotherapeutics 14.1.8.1. Overview 14.1.8.2. Product Portfolio 14.1.8.3. Profitability by Market Segments 14.1.8.4. Sales Footprint 14.1.8.5. Strategy Overview 14.1.8.5.1. Marketing Strategy 14.1.9. VCNBiosciences 14.1.9.1. Overview 14.1.9.2. Product Portfolio 14.1.9.3. Profitability by Market Segments 14.1.9.4. Sales Footprint 14.1.9.5. Strategy Overview 14.1.9.5.1. Marketing Strategy 14.1.10. DNAtrix 14.1.10.1. Overview 14.1.10.2. Product Portfolio 14.1.10.3. Profitability by Market Segments 14.1.10.4. Sales Footprint 14.1.10.5. Strategy Overview 14.1.10.5.1. Marketing Strategy 15. Assumptions & Acronyms Used 16. Research Methodology
Explore Healthcare Insights
View Reports